A Randomized, Open-Label, 4-Period Cross-Over Study to Investigate the Inter- and Intra-subject Variability of Dance 501 (Human Insulin Inhalation Solution and Inhaler) in Subjects with Type 1 Diabetes Mellitus (T1DM)
Latest Information Update: 30 Jan 2020
At a glance
- Drugs Insulin (Primary) ; Insulin lispro
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Aerami Therapeutics; Dance Biopharm
- 22 May 2019 Status changed from recruiting to completed.
- 05 Dec 2018 New trial record